NCT06517719 - Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

September 4, 2024

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2028

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

OTHER

lutetium (177Lu) vipivotide tetraxetan

This is an observational study. There is no treatment allocation. The decision to initiate lutetium vipivotide tetraxetan will be based solely on clinical judgement.

Trial Locations (17)

10249

RECRUITING

Novartis Investigative Site, Berlin

13125

RECRUITING

Novartis Investigative Site, Berlin

33611

RECRUITING

Novartis Investigative Site, Bielefeld

39120

RECRUITING

Novartis Investigative Site, Magdeburg

45147

RECRUITING

Novartis Investigative Site, Essen

52074

RECRUITING

Novartis Investigative Site, Aachen

53105

RECRUITING

Novartis Investigative Site, Bonn

54290

RECRUITING

Novartis Investigative Site, Trier

72076

RECRUITING

Novartis Investigative Site, Tübingen

78464

RECRUITING

Novartis Investigative Site, Konstanz

86179

RECRUITING

Novartis Investigative Site, Augsburg

89081

RECRUITING

Novartis Investigative Site, Ulm

93053

RECRUITING

Novartis Investigative Site, Regensburg

97080

RECRUITING

Novartis Investigative Site, Würzburg

09113

RECRUITING

Novartis Investigative Site, Chemnitz

06120

RECRUITING

Novartis Investigative Site, Halle S

07740

RECRUITING

Novartis Investigative Site, Jena